Aspen Pharmacare Holdings Limited (JSE:APN)

Aspen Pharmacare Holdings Ratios and Metrics

Market cap in millions ZAR. Fiscal year is July - June.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 8, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Market Capitalization	49,864	53,079	103,810	81,701	62,047	73,836
Market Cap Growth	-33.52%	-48.87%	27.06%	31.68%	-15.97%	12.88%
Enterprise Value	79,575	81,746	128,328	100,452	81,357	101,518
Last Close Price	112.30	116.89	224.02	172.83	127.83	147.38
PE Ratio	-	-	23.57	15.63	9.56	15.36
Forward PE	9.20	9.58	12.68	10.44	7.34	11.63
PS Ratio	1.15	1.22	2.32	2.01	1.61	1.96
PB Ratio	0.59	0.63	1.22	0.95	0.88	1.13
P/TBV Ratio	3.49	3.71	7.46	4.45	4.68	9.88
P/FCF Ratio	19.30	20.55	33.40	24.83	18.19	15.45
P/OCF Ratio	9.67	10.29	16.68	14.80	11.55	10.82
PEG Ratio	0.63	0.46	0.46	0.46	0.46	1.27
EV/Sales Ratio	1.84	1.89	2.87	2.47	2.11	2.69
EV/EBITDA Ratio	9.10	9.60	12.49	9.86	8.19	11.06
EV/EBIT Ratio	11.38	11.69	14.47	11.25	9.31	12.52
EV/FCF Ratio	30.81	31.65	41.29	30.53	23.85	21.24
Debt / Equity Ratio	0.43	0.43	0.43	0.34	0.31	0.38
Debt / EBITDA Ratio	4.13	4.13	3.47	2.82	2.20	2.66
Debt / FCF Ratio	13.98	13.98	11.73	8.90	6.52	5.21
Asset Turnover	0.32	0.32	0.33	0.33	0.35	0.31
Inventory Turnover	1.35	1.35	1.35	1.24	1.40	1.34
Quick Ratio	1.17	1.17	1.06	1.06	0.79	0.52
Current Ratio	2.21	2.21	1.81	1.92	1.48	0.89
Return on Equity (ROE)	-1.28%	-1.28%	5.15%	6.65%	9.50%	7.12%
Return on Assets (ROA)	3.18%	3.18%	4.06%	4.54%	4.94%	4.17%
Return on Capital (ROIC)	3.61%	3.61%	4.68%	5.35%	5.95%	5.01%
Return on Capital Employed (ROCE)	5.90%	5.90%	7.70%	8.00%	9.90%	11.10%
Earnings Yield	-2.17%	-2.04%	4.24%	6.40%	10.46%	6.51%
FCF Yield	5.18%	4.87%	2.99%	4.03%	5.50%	6.47%
Dividend Yield	1.85%	1.80%	1.60%	1.98%	2.55%	1.78%
Payout Ratio	-	-	34.63%	27.83%	18.43%	-
Buyback Yield / Dilution	0.04%	0.04%	-	1.94%	0.77%	-
Total Shareholder Return	1.89%	1.85%	1.60%	3.92%	3.32%	1.78%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.